2025-05-24 - Analysis Report
Okay, here's the report on Transmedics Group Inc (TMDX) based on the provided data, with a focus on key performance indicators and recent developments.

**Transmedics Group Inc (TMDX) Analysis**

**0. Executive Summary**

This report analyzes Transmedics Group Inc (TMDX), a company focused on medical technology, specifically organ preservation and transportation. The analysis considers relative performance against the S&P 500 (VOO), recent price action, technical indicators, news events, and financial performance. Overall, TMDX exhibits strong growth and profitability, but is also characterized by high volatility and risk.

**1. Relative Performance vs. S&P 500 (VOO)**

*   **Ticker:** TMDX
*   **Company Description:** Transmedics Group Inc is a medical technology company focused on organ preservation and transportation.
*   **TMDX Cumulative Return:** 239.21%
*   **VOO Cumulative Return:** 50.81%
*   **Absolute Deviation (Current):** 188.4
*   **Deviation Range:** Max: 292.1, Min: -69.8
*   **Relative Deviation:** 71.3

**Analysis:** TMDX has significantly outperformed the S&P 500. A relative deviation of 71.3 indicates that the current outperformance is positioned in the upper range of its historical deviation from the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha | Beta | Cap(B) |
|------------|--------|-------|-------|------|--------|
| 2019-2021  | -4.0%  | 63.4% | -57.0% | 0.0  | 0.7    |
| 2020-2022  | 140.0% | 68.3% | 134.0% | 0.0  | 2.1    |
| 2021-2023  | 95.0%  | 69.4% | 79.0%  | 0.3  | 2.7    |
| 2022-2024  | 147.0% | 82.8% | 130.0% | 0.3  | 2.1    |
| 2023-2025  | 120.0% | 82.8% | 93.0%  | 0.5  | 4.2    |

**Analysis:**

*   **CAGR:** Demonstrates strong compounded annual growth in recent periods (2020-2025).
*   **MDD:** High Maximum Drawdown (MDD) figures consistently in the 60-80% range suggests very high volatility and risk.
*   **Alpha:** Strong positive alpha indicates significant outperformance relative to its benchmark, particularly in the 2020-2024 periods.
*   **Beta:** Beta values range from 0.0 to 0.5. These values indicate that TMDX's price is not very sensitive to the overall market movements.
*   **Cap:** The company's capitalization has increased over time.

**2. Recent Price Action**

*   **Current Price:** 124.25
*   **Last Market Data:** {'price': 124.25, 'previousClose': 123.34, 'change': 0.74}
*   **5-day Moving Average:** 123.142
*   **20-day Moving Average:** 108.173
*   **60-day Moving Average:** 85.53

**Analysis:** The current price is above all three moving averages, indicating a strong uptrend.  The recent price increase (change: 0.74) shows continued positive momentum.

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.365 (Low Risk - Medium Risk boundary)
*   **RSI:** 85.12 (Overbought)
*   **PPO:** 0.0687
*   **Recent (20-day) Relative Deviation Change:** 3.3 (+): Short-term increase
*   **Expected Return (%):** 39.8%

**Analysis:**

*   **MRI:** The MRI suggests a relatively low-risk environment.
*   **RSI:** The RSI indicates that TMDX is currently overbought and may be due for a correction.
*   **PPO:** A positive PPO value indicates that the stock is in an uptrend.
*   **Relative Deviation:** The increase in relative deviation confirms the recent outperformance trend.
*   **Expected Return:** The high expected return suggests significant potential for future growth, but investors should be aware that past performance does not guarantee future results.

**4. Recent News & Significant Events**

*   **[2025-05-22]:** Major business developments, regulatory changes, or market events.
*   **[2025-05-20]:** Analysts discussing performance in the context of industry trends and global economic factors.
*   **[2025-05-24]:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **[2025-05-21]:** Market experts highlight both risks and opportunities.

**Analysis:** The news suggests that TMDX is experiencing significant events that are impacting its stock price. Investors should closely monitor company announcements and news for potential risks and opportunities.

**5. Recent Earnings Analysis**

| Date       | EPS  | Expected EPS |
|------------|------|--------------|
| 2025-05-08 | 0.7  | 0.29         |
| 2025-02-27 | 0.19 | 0.22         |
| 2024-10-28 | 0.12 | 0.29         |
| 2024-07-31 | 0.35 | 0.21         |
| 2024-04-30 | 0.35 | 0.03256      |

**Analysis:**  Transmedics Group Inc. has shown a strong performance in terms of earnings per share (EPS). Notably, the actual EPS significantly exceeded expectations in most quarters, particularly on 2025-05-08. This indicates a trend of the company outperforming analysts' estimates, which is generally viewed as a positive sign.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-03-31 | $0.14B  | 61.47%        |
| 2024-12-31 | $0.12B  | 59.21%        |
| 2024-09-30 | $0.11B  | 55.94%        |
| 2024-06-30 | $0.11B  | 60.59%        |
| 2024-03-31 | $0.10B  | 61.91%        |

**Capital and Profitability:**

| Quarter    | Equity | ROE   |
|------------|--------|-------|
| 2025-03-31 | $0.27B | 9.64% |
| 2024-12-31 | $0.23B | 3.00% |
| 2024-09-30 | $0.21B | 2.01% |
| 2024-06-30 | $0.19B | 6.42% |
| 2024-03-31 | $0.16B | 7.65% |

**Analysis:**

*   **Revenue:**  Revenue has shown consistent growth over the past five quarters, indicating increasing demand for Transmedics' products or services.
*   **Profit Margin:** The company maintains high and relatively stable profit margins, suggesting efficient cost management and strong pricing power.
*   **Equity:** Total equity has been steadily increasing, reflecting the company's growing net worth.
*   **ROE:** Return on Equity (ROE) fluctuates but generally shows a positive trend, indicating that the company is effectively using its equity to generate profits. The increase in ROE on 2025-03-31 suggests improved profitability relative to equity.

**7. Overall Analysis**

Transmedics Group Inc (TMDX) exhibits strong financial performance, reflected in significant revenue growth, high profit margins, and substantial outperformance compared to the S&P 500. The company's earnings have consistently exceeded expectations, further indicating its solid operational performance.

However, TMDX is characterized by high volatility, as indicated by the high MDD. The stock is currently overbought according to the RSI, suggesting a potential for short-term price correction. Recent news indicates that TMDX is undergoing significant business developments and market events, which investors should monitor closely.

**Conclusion:**

TMDX presents an attractive investment opportunity due to its strong growth prospects and financial performance. However, investors should be aware of the inherent volatility and potential risks associated with the stock. The recent overbought condition and ongoing significant events suggest the need for careful monitoring and risk management. A long-term, disciplined investment approach is advisable.
